DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...
DELRAY BEACH, Fla., June 4, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the biofertilizer market is projected to grow from USD 4.08 billion in 2026 and to...
TORONTO, June 3, 2026 /CNW/ - Ontario Nurses' Association (ONA) members at more than 46 long-term care homes across the province are hosting information pickets...
Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
SAN JOSE, Calif., June 2, 2026 /PRNewswire/ -- Today PremierOne Credit Union announced the launch of its new Beyond the Classroom Program, a relationship-focused...
WINNEMUCCA, Nev., June 2, 2026 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or "the Company"), is pleased to announce the results from its...
WINNEMUCCA, Nev., June 3, 2026 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or "the Company"), is pleased to announce the results from its...
WINNEMUCCA, Nev., June 2, 2026 /PRNewswire/ -- Hycroft Mining Holding Corporation (Nasdaq: HYMC) ("Hycroft" or "the Company"), is pleased to announce the results from its...